Idexx Laboratories continues to outperform with earnings, revenue beat
Select language to see a machine translation of this article. The original language of the Article is English and the translation is provided for your convenience.

Idexx Laboratories continues to outperform with earnings, revenue beat

Idexx Laboratories, a purveyor of veterinary diagnostic tools and products that cater to the trend to treat pets increasingly like members of the family, reported earnings last week that justified the ascent of its share price, year to date. The company saw beats on the top- and bottom-lines, driven, once again, by strong performance from its Companion Animal Group (CAG). This segment of the business is responsible for helping millennials cater to their “fur babies” with a range of testing equipment and services for pets that simply didn’t exist ten years ago.

Idexx Laboratories’ share price has been on a tear this year so far, rising by 34%

07 05 idexx

Source: Yahoo Finance

Idexx said that revenues rose by 7%, year on year, to $576.1 million. That’s a beat of $1 million against analysts’ expectations. The company also surprised on earnings, delivering net income of $102.7 million. That works out as $1.17 per share – a 16% increase from the same year-ago quarter and an 11c outperformance against the Street’s predictions.

Offering a brief summation and strategic overview on the company’s earnings call, chairman and CEO Jonathan Ayers said: “Our strong business performance continued in the first quarter, sustaining high organic growth in CAG Diagnostics recurring revenues. With great runway ahead and a robust start to the year, we are well-positioned to execute our unique innovation-based and multi-modality strategy, enabled by our expanded global commercial capability, as we continue to deliver outstanding financial results aligned with our long-term goals.”

Disclosure

Dominion holds Idexx Laboratories in its Global Trends Luxury Fund.


If you would you like to receive the Newsfeeds daily, please click here to sign up now!

Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
0.0/5 rating (0 votes)

Disclaimer
The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.